What makes Ipamorelin a research favorite
The 1998 publication characterizing Ipamorelin (Raun et al., Eur J Endocrinol) describes it as a selective growth-hormone secretagogue — research suggests reduced reported activity on cortisol and prolactin compared to earlier GHRP-family research compounds. Subsequent comparative literature supports the selectivity claim.